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OBJECTIVES This investigation evaluated the relationship between obesity and B-type natriuretic peptide
(BNP) in heart failure.
BACKGROUND Obesity is a major risk factor for the development of heart failure, but the precise mechanisms
remain uncertain. Physiologically, natriuretic peptides and lipolysis are closely linked.
METHODS A total of 318 patients with heart failure were evaluated between June 2001 and June 2002.
Levels of BNP were compared in obese (body mass index [BMI] 30 kg/m2) and nonobese
(BMI 30 kg/m2) patients with respect to New York Heart Association functional class and
lean body weight–adjusted peak aerobic oxygen consumption. In a subset of 36 patients,
plasma levels of tumor necrosis factor-alpha, interleukin-6, and soluble intercellular adhesion
molecule-1 were measured.
RESULTS The population’s BMI was 29.4  6.6 kg/m2; 24% were lean (BMI 25 kg/m2), 31%
overweight (BMI 25 to 29.9 kg/m2), and 45% obese (BMI 30 kg/m2). Obese patients
were younger, more often African American, and more likely to have a history of antecedent
hypertension, but less likely to have coronary artery disease and with only a trend toward
diabetes mellitus. Levels of BNP were significantly lower in obese than in nonobese subjects
(205  22 and 335  39 pg/ml, respectively; p  0.0007), despite a similar severity of heart
failure and cytokine levels. Multivariate regression analysis identified BMI as an independent
negative correlate of BNP level. There were no differences in emergency department visits,
heart failure hospitalization, or death between the obese and nonobese patients at 12-month
follow-up.
CONCLUSIONS Our investigation indicates that a state of reduced natriuretic peptide level exists in the obese
individual with heart failure. (J Am Coll Cardiol 2004;43:1590–5) © 2004 by the American























The role of natriuretic peptides in the clinical expression of
hronic heart failure (CHF) has been established (1).
ontemporary investigations have correlated the levels of
irculating B-type natriuretic peptide (BNP) with the se-
erity of heart failure, and it can provide incremental
efinement for improving the diagnosis of heart failure (1,2).
ther studies have alluded to variations in the expression of
his hormone as a function of age, gender, and renal
ysfunction (3,4).
The influence of obesity on the development of cardio-
ascular disease has also been well established (5). In
articular, obesity is a known factor that has an impact on
ystolic and diastolic ventricular function and has also been
dentified as a major risk factor for the development of
oronary artery disease and heart failure (6–8). Physiolog-
cally, natriuretic peptides and lipolysis have been closely
inked, and adipose tissues are intimately related to the
atriuretic clearance receptor (9,10). Hence, this raises the
ossibility that the pathophysiologic mechanisms underly-
ng the relationship between obesity and cardiovascular
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Manuscript received July 24, 2003; revised manuscript received October 6, 2003,Accepted October 7, 2003.isease outcomes could at least partially be related to the
mpact of natriuretic peptides (9,10).
Therefore, we hypothesized that the state of obesity and
eart failure could be associated with alterations in the
eripheral expression of natriuretic peptides. Thus, this
nvestigation was designed to evaluate the relationship
etween obesity and circulating levels of BNP.
ETHODS
tudy design. A total of 318 patients with CHF were
valuated in our heart failure center between June 2001 and
une 2002. All patients received a careful history and
hysical examination by a heart failure specialist physician
ho was blinded to BNP data. To be included in this
nalysis, patients had to have CHF (with or without
besity) for at least six months and receive stable doses of
heir medications with no recent increases in symptoms or
he need for intravenous medication support for at least six
eeks before evaluation. Thus, this cohort did not selec-
ively comprise those with obesity-induced heart failure.
hose patients with an acute coronary syndrome, new-onset
trial arrhythmia, percutaneous or surgical coronary revas-
ularization or other cardiac surgery, or severe renal dys-
unction (serum creatinine 3.0 mg/dl or current dialysis)
ithin the previous three months were likewise excluded.
he severity of CHF was categorized by New York Heart

































































































1591JACC Vol. 43, No. 9, 2004 Mehra et al.
May 5, 2004:1590–5 Obesity and BNPerformance of cardiopulmonary stress testing (CPX) in
rder to establish peak aerobic capacity in all patients.
etailed demographic variables and clinical data were col-
ected at the time of study performance. Additionally, a
ubgroup of patients underwent evaluation of pro-
nflammatory cytokines in order to assess the status of CHF
ith BNP levels and obesity. Our Institutional Review
oard approved the study.
easurement of BNP. The bioactive BNP level was
nalyzed at the time of clinical assessment. For each BNP
easurement, 5 ml of whole blood was collected into tubes
ontaining potassium EDTA (1 mg/ml blood) and mea-
ured using the Triage BNP test (Biosite Diagnostics Inc.,
an Diego, California). This test is a fluorescence immu-
oassay for the quantitative determination of BNP in whole
lood and plasma specimens. The turnaround time for the
ssay is 15 to 20 min.
ssessment of obesity parameters, CPX, and echo-
ardiography. Obesity was defined on the basis of a body
ass index (BMI) of 30 kg/m2. Levels of BNP were
ompared in the obese and nonobese (BMI 30 kg/m2)
atients with respect to NYHA functional class and lean
ody weight–adjusted peak aerobic oxygen consumption
VO2). Cardiopulmonary stress testing was accomplished
sing a ramping treadmill protocol, and breath-to-breath
n-line gas analysis was performed using a MedGraphics
PXID metabolic cart (St. Paul, Minnesota). Incremental
ata, including minute ventilation, VO2, and carbon dioxide
roduction, were collected, and maximal VO2, anaerobic
hreshold, and respiratory exchange ratio were calculated.
xygen consumption was corrected for body fat and was
eported as lean body mass–adjusted VO2, as we reported
reviously (11). Echocardiography was performed in all
atients and interpreted by investigators blinded to the
linical data and BNP data. Renal function was evaluated by
sing serum creatinine measurements (mg/dl) and by the
alculated glomerular filtration rate.
ytokine substudy. In a subset of 36 patients with NYHA
lass III heart failure, we measured plasma levels of tumor
ecrosis factor-alpha, interleukin-6, and soluble intercellular
dhesion molecule-1 by means of enzyme-linked immuno-
ssay. These cytokines were determined in obese and
Abbreviations and Acronyms
BMI  body mass index
BNP  B-type natriuretic peptide
CHF  chronic heart failure
CI  confidence interval
CPX  cardiopulmonary stress testing
LV  left ventricular
LVEF  left ventricular ejection fraction
NYHA  New York Heart Association
VO2  oxygen consumptiononobese patients who were matched with respect to the alinical severity of heart failure, left ventricular ejection
raction (LVEF), peak exercise VO2, and medications used.
utcomes analysis. We also evaluated the combined end
oints of emergency department visits or hospitalizations
or CHF or death in obese heart failure patients compared
ith nonobese subjects at 12 months after study entry.
tatistical analysis. Normally distributed data are reported
s the mean value  SD. Categorical variables were com-
ared using the likelihood ratio chi-square test. With
ontinuous variables, group mean values were compared
sing the unpaired Student t test, as long as the variables
ere normally distributed within each group and the vari-
tion of scores in the two groups were not reliably different.
he normality assumption was evaluated by examining the
istribution of data (via histograms). If the data distribution
id not follow the normality assumption, the Wilcoxon
ank-sum test was utilized. Further multivariate analyses
ere performed to evaluate the independent relationship of
MI and BNP levels in concert with demographic variables
age, race, and gender), structural cardiac functional indexes
LVEF and LV end-diastolic diameter), severity of heart
ailure (NYHA class, lean peak VO2), and renal function.
ox proportional hazard regression analysis was used to
etermine the independent predictors of event-free survival
nd included BMI, age, gender, ischemic versus nonisch-
mic cardiomyopathy, functional classification, LVEF, renal
unction, BNP levels, and peak VO2. All analyses were
erformed using StatView version 4.5 (Abacus Concepts
nc., Berkeley, California), and statistical significance was
et at p  0.05.
ESULTS
atients. The study included 318 consecutive patients
age 57  14 years; 57% men; 53% white) with CHF
LVEF 31  17%). All patients received maximal treat-
ent using conventional therapy. Thus, 89% received
ngiotensin-converting enzyme inhibitors or angiotensin
eceptor blockers and 71% received beta-blockers. All re-
eived diuretics to “dry” weight. The total population’s BMI
as 29.4  6.6 kg/m2; 24% were lean (BMI 25 kg/m2),
1% overweight (BMI 25–29.9 kg/m2), and 45% obese
BMI 30 kg/m2). Obese patients with CHF were
ounger, more often African American, and more likely to
ave a history of antecedent hypertension, but less likely to
ave coronary artery disease and with only a trend toward
iabetes mellitus (Table 1).
omparison of BNP levels in obese and nonobese
atients. Levels of BNP were significantly lower in obese
han in nonobese subjects (205  22 and 335  39 pg/ml,
espectively; p  0.0007). These differences persisted even
hen the patients were regrouped into lean (BNP 366  47
g/ml), overweight (BNP 309  34 pg/ml), or obese (BNP
05  22 pg/ml, p  0.01 for trend). However, there was no
ignificance between the lean and overweight groups (p 0.3),

























































obese and nonobese patients (lean and overweight).
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Obesity and BNP May 5, 2004:1590–5ignificantly less (p  0.009). Thus, the group of overweight
ubjects was similar to the lean group with regard to BNP
evels (Figs. 1A and B), but the differences in BNP levels
etween the obese and nonobese groups persisted even though
hey had a similar functional class. Thus, the LVEF, VO2
orrected for lean body mass, serum creatinine, and glomerular
ltration rate were similar between the two groups. To further
valuate the influence of age and its possible interaction with
NP levels in the context of obesity, we divided the cohort into
he elderly (65 years old) and nonelderly (65 years old) and
ound that the relationship of obesity and decreased BNP levels
ersisted. Thus, the elderly obese patients had 28% lower BNP
evels compared with elderly nonobese patients (BNP 290 
0 vs. 405 48 pg/ml, p 0.03). Similarly, the younger (65
ears old) obese patients demonstrated 40% lower BNP levels
ompared with younger nonobese patients (175  24 vs. 294
35 pg/ml, p 0.006). No significant interaction of diabetes
ellitus as a determinant of BNP levels in the obese and
onobese subjects was noted. Regression analysis of BNP levels
nd BMI as a continuous variable revealed a weak but
ignificantly inverse relationship between the two variables (r
0.36, p  0.002) (Fig. 2).
ultivariable predictors of BNP levels. Multivariate re-
ression analysis identified BMI as an independent negative
orrelate of BNP levels (t  3.428, p  0.0007). Other
ndependent correlates included age (t  3.001, p 
.0003), female gender (t  2.584, p  0.01), serum




(n  143) p Value
ge (yrs) 60  13 56  13 0.04
ale gender (%) 59 53 0.3
aucasian (%) 57 43 0.02
istory of hypertension (%) 69 86 0.004
oronary artery disease (%) 67 55 0.04
iabetes mellitus (%) 32 41 0.07
VEF (%) 30  17 32  17 0.1
VEDD (mm) 5.6  1.1 5.7  1.0 0.3
YHA class (%) 0.9
I/II 67 70
III/IV 33 30
BP (mm Hg) 126  23 127  20 0.7
BP (mm Hg) 69  15 69  14 0.8
emoglobin (gm/dl) 13.1  1.8 13.1  1.7 0.9
ematocrit (%) 39.8  4.7 39.8  4.9 0.9
lood urea nitrogen (mg/dl) 22  13 24  14 0.2
erum creatinine (mg/dl) 1.3  0.5 1.3  0.5 0.5
FR (ml/min) 71  18 68  14 0.4
O2 lean (ml/kg/min) 22  7 24  5 0.2
CE inhibitor or ARB (%) 90 91 0.8
eta-blocker (%) 76 80 0.1
iuretics (%) 89 90 0.8
ata are presented as the mean value  SD or percentage of subjects.
ACE  angiotensin-converting enzyme; ARB  angiotensin receptor blockers; DBP  diastolic blood pressure; GFR 
lomerular filtration rate; LVEF  left ventricular ejection fraction; LVEDD  left ventricular end-diastolic diameter; NYHAigure 1. (A) Obese patients have lower circulating levels of B-type
atriuretic peptide (BNP) compared with both lean and overweight
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May 5, 2004:1590–5 Obesity and BNP.0007). In particular, we did not find any significant
ndependent influence of diabetes mellitus on BNP levels.
ytokine substudy findings. Although BNP levels were
ignificantly lower in the obese (n  16, 305  124 pg/ml)
ersus nonobese (n  20, 510  141 pg/ml, p  0.01 by
ilcoxon rank-sum test) comparison, there were no differ-
nces (p  NS by Wilcoxon rank-sum test) in the three
ytokines between these subgroups (Table 2). These find-
ngs suggest that the differences in BNP levels in obese
atients were not related to differences in circulating levels
f pro-inflammatory cytokines.
utcomes. There were no significant differences in the
ime to first event (emergency department visit or hospital-
zation for CHF or death) between the obese and nonobese
atients (Fig. 3). Moreover, the event rate for the entire
ohort at one year was 27%, and this was not different
etween the obese (25%) and nonobese (29%) patients. In a
ox proportional hazards model stratified by obese and
onobese patients and including age (95% confidence inter-
al [CI] 0.97 to 1.02), female gender (95% CI 0.68 to 2.8),
VEF (95% CI 0.97 to 1.01), serum creatinine (95% CI
.73 to 1.7), and BNP level (95% CI 0.99 to 1.01) as
ovariates, there were no significant interactions noted.
nly a higher NYHA class predicted a worse survival (CI
.17 to 2.9, p  0.02).
Table 2. Cytokine Substudy
(
BNP (pg/ml) 3





Data are presented as the mean value  SD.
BNP  B-type natriuretic peptide.ISCUSSION
his study demonstrates that obesity is an important and
ndependent determinant of peripheral BNP expression in
atients with CHF. The implications of these findings not
nly extend to the usefulness of BNP as a diagnostic test in
bese patients with heart failure, but also provide important
nsight into certain potential underlying pathophysiologic
echanisms that relate to the development of heart failure
n obese patients. Thus, patients with obesity, even before
evelopment of heart failure, have an expanded intravascular
plasma) volume associated with an increased cardiopulmo-
ary volume (6). Several recent studies have shown that
atriuretic peptide levels are reduced in the obese state,
artly related to altered clearance receptors and peptide
egradation (9,10). These lines of evidence, coupled with
ur findings, provide endorsement for the presence of a
educed natriuretic response in the state of obesity. The
uggestion that there may be increased clearance of BNP by
dipose tissue raises the interesting possibility that there
ay be early loss of natriuretic-mediated vasodilation, lesser
ntagonism of the rennin-angiotensin system, or loss of
atriuretic ability in obese patients.
Several investigations have alluded to obesity as a major




(n  20) p Value
124 510  141 0.01
4.2 3.5  1.5 0.46
6.7 8.6  5.3 0.89
75 292  131 0.64igure 2. This figure depicts the raw data demonstrating a significant
nverse correlation between circulating B-type natriuretic peptide (BNP)





64 igure 3. No difference in emergency department visits, heart failure
ospitalization, or death between obese (triangles) and nonobese (circles)
atients at 12-month follow-up was noted in the obese and nonobese
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Obesity and BNP May 5, 2004:1590–5egardless of gender (8). Why the heart fails as a result of
besity continues to be a matter of intense investigative
crutiny. Several lines of evidence have pointed to hemody-
amic overload, lipoapoptosis, impaired fatty acid oxidation,
r the concerted effects of diffuse vascular damage, which are
resent early in childhood (12–15). Obesity is associated
ith an increased prevalence of most cardiovascular risk
actors, including systemic hypertension, diabetes mellitus,
yperlipidemia, and LV hypertrophy (16). Moreover, be-
ause of coexistent volume overload with obesity and pres-
ure overload with frequent hypertension, eccentric and
oncentric LV hypertrophy is expected (6). Our study
upports this notion, as obese heart failure patients were
ounger and had a more prevalent history of hypertension
nd perhaps diabetes mellitus. Nevertheless, the precise
echanisms linking obesity to heart failure remain unre-
olved.
As already suggested, the natriuretic peptide system and
diposity are closely linked. Lipolysis is mediated by cat-
cholamines (stimulation of lipolysis) and insulin (inhibi-
ion of lipolysis) (17). More recently, natriuretic peptides
ave been shown to be important stimuli for lipolysis in
umans and similar in potency to catecholamines (18).
urthermore, since adipose cells express the natriuretic
learance receptor (19), in obese patients, a state of reduced
atriuretic peptide concentration could occur, explaining
he increased sodium retention and volume expansion char-
cteristic of obesity-related hypertension (6). Fasting and
eight loss are known to decrease expression of adipose
ellular natriuretic peptide clearance receptors (20). Con-
ersely, obesity is common after menopause, and it has been
uggested that the decreased availability of circulating na-
riuretic peptides due to increased expression of the natri-
retic clearance receptor could explain, at least in part, the
ncrease in cardiovascular disease after menopause (21). Our
tudy lends credence to these potential mechanisms and
uggests that one possible explanation for the earlier expres-
ion of heart failure in the presence of obesity could be
elated to reduced circulating natriuretic peptides.
Thus, a paradox has emerged in the obese patient. On
ne hand, heart failure is increased in obese patients, but
lternatively, a survival advantage in heart failure has been
eported (22–24). Several lines of evidence have been
uggested for diminished activation of natriuretic peptides,
nhanced protection against endotoxin/inflammatory cyto-
ines, and increased nutritional and metabolic reserve. All of
hese possibilities may explain the observation of better
urvival in obese patients with heart failure (25–28). As
oted in our study, event-free survival was not different in
bese and nonobese heart failure patients. Other studies
ave demonstrated this apparent obesity paradox by includ-
ng patients with severe heart failure and cardiac cachexia.
n the current study, no differences in the circulating
ro-inflammatory cytokines were found, and the severity of
eart failure (as evaluated by lean body weight–adjusted
O2) was similar in obese and nonobese patients. Thesebservations suggest that the lower levels of natriuretic
eptides in obesity did not confer a more favorable progno-
is. This finding lends further credence to the concept that
state of reduced BNP level exists in obese patients with
eart failure.
onclusions. Obesity is associated with significantly lower
eripheral expression of natriuretic peptides in heart failure.
ur investigation indicates that a state of reduced natri-
retic peptide level exists in the obese individual with heart
ailure.
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